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Abstract
Background & Aims: Variations in intestinal microbiota may influence acet-
aminophen metabolism. This study aimed to determine whether intestinal
microbiota are a source of differential susceptibility to acetaminophen-
induced hepatotoxicity. Methods: Conventionally housed C3H/HeH (CH)
and C3H/HeH germ-free (GF) mice were administered a 200 mg/kg IP dose
of acetaminophen. The severity of hepatotoxicity at 8 h was assessed by his-
tology and biochemical indices. A urinary metabolic profile was obtained
using 1H-NMR. Baseline hepatic glutathione content and CYP2E1 expression
were quantified. An additional group of C3H/HeJ (LPS-r) mice were assessed
to determine the contribution of LPS/TLR4 signalling. Results: Baseline glu-
tathione levels were significantly reduced (P = 0.03) in GF mice. CYP2E1
mRNA expression and protein levels were not altered. Interindividual vari-
ability did not differ between GF and CH groups. No significant differences
in the extent of hepatocellular injury (ALT or percentage necrosis) were dem-
onstrated. However, a milder acute liver failure (ALF) phenotype was shown
in GF compared with CH mice, with reduced plasma bilirubin and creatinine
and increased blood glucose. Differential acetaminophen metabolism was
demonstrated. GF mice displayed a higher urinary acetaminophen-sulphate:
glucuronide ratio compared with CH (P = 0.01). Urinary analysis showed
metabolic differentiation of GF and CH groups at baseline and 8 h (cross-
validated ANOVA P = 1 9 10-22). Interruption of TLR4 signalling in LPS-r
mice had additional protective effects. Conclusion: Variations in intestinal
microbiota do not fully explain differential susceptibility to acetaminophen-
induced hepatotoxicity. GF mice experienced some protection from second-
ary complications following acetaminophen overdose and this may be
mediated through reduced TLR4/LPS signalling.
Acetaminophen is a commonly used analgesic and anti-
pyretic medicine. Since it was first recognised as a
potent hepatotoxin in the 1960s, acetaminophen over-
dose has become the most common cause of acute liver
failure in the UK and USA (1–3).
In patient populations, there is a wide range of interin-
dividual susceptibility to the hepatotoxic effects of acet-
aminophen, which is incompletely explained by known
risk factors such as chronic alcohol abuse or nutritional
deficiencies (4). Patient outcome following acetamino-
phen-induced acute liver failure does not correlate with
the dose of acetaminophen ingested (5). Recently, evi-
dence has emerged that a proportion of the adult popula-
tion experience elevations in liver transaminase levels
indicative of hepatocellular damage following the con-
sumption of doses of acetaminophen within the therapeu-
tic range (4 g/24 h) over short periods (7–14 days) (6, 7).
Murine models of acetaminophen toxicity are com-
monly used to examine the underlying mechanisms of
hepatocellular damage in this condition and more gen-
erally as a model of acute, sterile liver inflammation.
Unexplained variability in the response of genetically
identical mice to toxic doses of acetaminophen is widely
recognised and it has been hypothesised that this vari-
ability may be accounted for by differences in intestinal
microbiota (8).
Differences in host intestinal microbiota are
increasingly recognised as a potential source of inter-
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individual variation in response to drugs and toxins
(9). In the particular case of acetaminophen han-
dling, Clayton et al. found an association between
predose, gut-derived urinary metabolites and response
to a therapeutic dose of acetaminophen in human
subjects. Higher levels of predose urinary p-cresol
sulphate predicted a reduction in the acetaminophen-
sulphate:acetaminophen-glucuronide ratio in post-
dose urine (10). It was postulated that gut-derived
microbial metabolites might increase acetaminophen
toxicity.
The theoretical mechanisms by which gut microbi-
ota might influence host susceptibility to acetamino-
phen-induced hepatotoxicity are numerous. Firstly, it
has been shown that bacterial-derived metabolites are
capable of up-regulating some cytochrome p450
hepatic enzymes (11, 12). This has been demon-
strated for members of the CYP family including
CYP3A4, CYP1A2, CYP2A6, though not for CYP2E1
itself. Secondly, depletion of hepatic sulphonation
capacity through competitive inhibition by bacterially
derived metabolites can occur and could theoretically
drive a greater proportion of the drug to be oxidised
to toxic product by the CYP450 enzyme system.
Thirdly, intestinal bacteria have been shown to
hydrolyse conjugated acetaminophen to release free
drug during the enterohepatic circulation of acetami-
nophen metabolites, thus potentially enhancing an
individual’s exposure to the active drug for any given
dose ingested (13, 14). Finally, bacterially derived
products, such as LPS, trafficking in the portal vein
to the liver have been implicated in the exacerbation
of liver disorders through their activation of hepatic
TLR receptors. In acetaminophen-induced hepatotox-
icity, the blocking of endogenous LPS activity with
an inhibitory peptide has been shown to ameliorate
liver injury, suggesting a role for endogenous micro-
bial products in the pathophysiology of drug-induced
hepatic injury (15).
In this study, we hypothesised that intestinal microbi-
ota contribute to the development and severity of acute
acetaminophen-induced hepatotoxicity and that this
effect is partly modulated through LPS-TLR4 signalling.
The influence of intestinal microbiota on susceptibility
to hepatotoxicity was assessed in germ-free and conven-
tionally housed mice. Baseline differences in factors
known to influence hepatotoxicity, such as hepatic glu-
tathione reserves and CYP2E1 expression were first
examined and then the severity of hepatotoxicity
assessed with biochemical indices and histological mea-
surement of necrosis. A third group of LPS-resistant
mice were used to determine whether intact LPS-TLR
signalling was an important determinant of susceptibil-
ity to acetaminophen-induced hepatotoxicity. The influ-
ence of gut microbiota on the metabolism of
acetaminophen was additionally studied in germ-free
and conventionally housed mice using urinary NMR
profiling.
Materials and methods
Animals
All research using live animals was approved by the local
ethics committee (MRC Harwell) and carried out under
Home Office supervision in accordance with the Animal
(Scientific Procedures) Act 1986 (UK). All efforts were
taken to minimise animal suffering. Three experimental
groups of male animals aged 8–11 weeks were used. The
control group (CH) was composed of 20 C3H/HeH
mice housed under standard ‘specific pathogen free’
conditions (12 h light/dark cycle, temperature
21 ± 2°C, humidity 55 ± 10%) and provided with a
standard commercial diet (SDS, UK) and ad libitum
access to drinking water. The group (GF) of nine C3H/
HeH mice was from a germ-free colony maintained at
the same facility under strict sterile conditions in a posi-
tive pressure isolator (Harlan Isotec). Complete sterility
of animals within the germ-free colony was validated by
regular swabs, faeces and urine cultures and bacterial
16s RNA PCR assays. The third group (LPS-r) was com-
posed of 10 C3H/HeJ mice maintained under SPF con-
ditions as per control group. C3H/HeJ mice are derived
from the same founder strain as C3H/HeH mice and
share significant genetic homology, but are known to
carry a missense mutation within the third exon of their
TLR4 receptor gene (predicted to replace proline with
histidine at position 712) that renders them relatively
LPS-resistant (16).
A further 10 GF and 10 CH mice between 8–12 weeks
of age were culled without acetaminophen dosing. Liver
tissue was snap frozen in liquid nitrogen then stored at
80°C.
Acetaminophen dosing
Following overnight fast, mice were weighed and a sin-
gle intraperitoneal dose of 200 mg/kg of acetaminophen
dissolved in warm saline was administered.
Sample collection for biochemistry and histology
Blood was collected via cardiac puncture at 8 h (T8),
under terminal anaesthesia with pentobarbital. The liver
was fixed in formalin.
Biochemical analysis of plasma T8 samples was per-
formed on a Beckman Coulter AU680 semi-automated
clinical chemistry analyser, using the manufacturer’s
instructions, parameter settings and reagents for mea-
surement of alanine transaminase (ALT), bilirubin,
glucose and creatinine.
Formalin-fixed liver tissue was embedded in paraffin,
sectioned and stained with haematoxylin and eosin
(H&E). A quantitative necrosis score was generated by a
point-scoring technique using a digital 100 square grid
over each of the 10 images per mouse with the reviewer
blinded to the experimental group.
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Glutathione assay
Baseline liver samples from 10 GF and 10 CH mice were
assayed for total glutathione using the ApoGSHTM Glu-
tathione Detection Kit (BioVision, Milpitas, CA, USA)
according to manufacturer’s instructions.
CYP2E1 Expression by RT-PCR and ELISA
RNA was extracted from snap-frozen liver tissue using
TRIzol reagent (Life Technologies, Carlsbad, CA,
USA) according to manufacturer’s instructions. 1 lg of
RNA was reverse transcribed using a Quantitect RT Kit
(Qiagen, Dusseldorf, Germany). Gene Expression Assay
Mm00491127 specific to murine CYP2E1 was used and
B2M, SDHA and 18s ribosomal RNA served as reference
genes (TaqMan Gene Expression Assays Mm00437762,
Mm01352363 and Mm03928990 respectively) (Life
Technologies). Biological replicates of five GF and five
CH mice were used and each reaction run in triplicate.
Results were analysed using a DDCT method using the
geometric means of the reference genes.
Snap-frozen liver tissue was thoroughly homogen-
ised, protein content measured and normalised to
1 mg/ml. CYP2E1 levels in the liver homogenates were
measured by ELISA (CSB-EL006425MO, Cusabio,
Wuhan, China) according to the manufacturer’s
instructions.
Hepatic cytokine measurements
Hepatic cytokines (TNFa, IL-1b, IFNc and IL-6)
were measured in liver homogenates (as above).
Exactly 10ug of total protein was used per sample
and cytokines quantified in duplicate using a MSD
Multi-spot cytokine assay (Mesoscale Discovery
Rockville, MD, USA) according to the manufacturer’s
instructions.
Urinary NMR metabolic profiling
Urine samples were collected from all mice 24 h prior
to acetaminophen dosing (T-24 unfasted) and at base-
line (T0) from fasted mice. Urine was then collected at
2 h post-dosing from the germ-free mice and 10 of the
CH controls for quantification of acetaminophen
metabolites (T2). Finally, urine samples were collected
from all GF and CH mice at eight hours post-dosing
(T8).
All urine samples were collected by clean catch into a
sterile microcentrifuge tube that was placed at 4°C for a
maximum of 1 h before storage at 80°C.
In preparation for NMR studies, a urine volume of
10 ll was mixed with 20 ll sterile water and 30 ll of
0.2M phosphate buffer [pH7.4, containing 20% D2O to
provide an NMR field frequency lock and 0.5 mM
Trimethylsilyl-propionic acid (TSP) for internal
chemical shift reference]. The solution was transferred
to a 1.7 mm OD capillary tube, placed within a 5 mm
micro NMR tube (New Era, Vineland, New Jersey,
USA). Urinary NMR spectra were acquired using a
JEOL 500 MHz Eclipse + NMR spectrometer housed at
MRC Harwell. Water presaturation was used for all data
acquisitions. The spectral width was 15 ppm, pulse
angle 90°, acquisition time 4.36 s and relaxation delay
2 s. Exactly, 32K data points were acquired per collect
and 256 transients were summated. The receiver gain
was constant for all samples. The resulting free induc-
tion decay was zero filled and multiplied by an exponen-
tial function corresponding to 0.3 Hz line broadening
prior to Fourier Transformation. The NMR spectra were
manually phased using the JEOL Delta.
Data analysis
Prior to statistical analysis, all NMR spectra were
baseline corrected to a 4th degree polynomial, zero
filled by a factor of 2 and referenced with the TSP
peak set to 0.00 ppm using KIA version 8.x (Bio-Rad,
Philadelphia, USA). NMR spectral resonances were
assigned according to the literature (17). The reso-
nances attributable to residual water and urea (d 4.6–
6.4 ppm) were excluded from further analysis. NMR
spectra were normalised to the total spectral integral
in the range d = 0.2–10 ppm (excluding 4.6–
6.4 ppm). Spectra were bucketed (total buckets 937)
using the Intelligent Bucketing algorithm and mean
centred. Principal Components Analysis (PCA) was
used as a unsupervised method for data visualisation
and outlier identification. Supervised regression mod-
elling was performed on the mean centred data set
using Partial Least Squares Discriminant Analysis
(PLS-DA) within Pirouette v 4.0 (Infometrix, Bothell,
WA, USA). Validation was performed using leave one
out cross validation. Individual metabolites were inte-
grated within KnowItAll, summed and normalised as
above and compared using the Kruskal–Wallis test
within GraphPad Prism version 4 (SanDiego, CA,
USA).
Plasma biochemistry results were compared with a
Kruskal–Wallis test and post hoc Dunn’s testing to
account for multiple comparisons.
Results
Baseline hepatic glutathione and CYP2E1 levels
Total hepatic glutathione levels were quantified in GF
and CH acetaminophen-na€ıve mice to determine steady
state glutathione stores. Germ-free mice showed a sig-
nificantly reduced hepatic glutathione content (mean
7.26 +/ 0.92 lmol/g of liver tissue) compared with
CH mice (mean 8.36+/0.95 lmol/g of liver tissue)
(P = 0.029 Mann–Whitney U-test, Fig. 1A).
The relative hepatic expression of CYP2E1, which is
the predominant enzyme responsible for metabolising
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acetaminophen to its reactive metabolite NAPQI, was
determined in the two groups using RT-PCR and levels
of protein quantified by ELISA. There were no signifi-
cant differences in gene expression or protein levels of
CYP2E1 between GF and CH mice (Fig. 1B and C
respectively).
Post-dosing biochemistry, histology & cytokine
measurements
At 8 hours post-dosing with acetaminophen, biochemi-
cal measures of acute liver failure and multi-organ dys-
function (bilirubin, glucose and creatinine) were
assessed in the three groups of mice. There was a signifi-
cant difference between groups in the bilirubin, glucose
and creatinine levels (Fig. 2A, B & C). GF and LPS-r
mice showed lower bilirubin levels [GF (mean 5.3+/
0.3 lmol/L), LPS-r (mean 3.1+/0.3 lmol/L)] than
CH mice (mean 7.6+/0.7 lmol/L) [Kruskal–Wallis
P = 0.0001, (Dunn’s CHvGF P = ≤0.05, CHvLPSr
P = ≤0.0001)] and higher glucose levels (GF 8.14+/
0.38 mmol/L, LPS-r 9.03+/0.57 mmol/L) than CH
mice (CH 7.06+/0.25 mmol/L) [Kruskal–Wallis
P = 0.009 (Dunn’s CHvGF P = ns, CHvLPSr
P = ≤0.01)]. Creatinine levels varied significantly
between the three groups with the CH groups having
higher levels (27.27+/1.9 lmol/L) compared to the GF
(18.96+/2.0 lmol/L) and LPS-r (14.05+/1.0 lmol/
L) groups [Kruskal–Wallis P = 0.0001 (Dunn’s CHvGF
P = ≤0.05, CHvLPSr P = ≤0.0001)].
Alanine Transaminase values showed considerable
variation within each group, but demonstrated good
correlation with the hepatic necrosis score (Spearman
r = 0.78, P = <0.0001). There was no significant differ-
ence between the mean ALT for the three groups (CH
14656+/6938, GF 10747+/6923, LPS-r 10052+/
10834, Kruskal–Wallis P = 0.16) (see Fig. 2D).
Review of H&E-stained hepatic sections showed the
classical appearance expected in acetaminophen toxicity
of centrilobular necrosis. In some of the more severely
affected mice, extensive hepatic haemorrhage was
observed (see Fig. 3A for representative images). The
mean percentage hepatic necrosis was 64.2% +/15.2
(range 37–87%) for CH, 67.4% +/16.5 (range 44–
84%) for GF and 59.8% +/26.0 (range 27–94%) in
LPS-r mice. No significant difference was demonstrated
between groups (Kruskal–Wallis test P = 0.79) (see
Fig. 3B).
Hepatic cytokines were measured in liver homogenates
from the CH, GF and LPSr groups at 8 h post-injury.
There was a non-significant trend for lower levels of NF-
jB-dependent and inflammasome-associated cytokines,
TNFa, IL-1b and Il-6 in the LPSr mice (Fig. S1C).
NMR
Baseline urinary spectra & taurine integrals
Principle components analysis (PCA) and a Partial Least
Squares Discriminant Analysis (PLS-DA) of the unfast-
ed (T-24) baseline urinary spectra from GF and CH
mice showed a clear separation between groups. Thus,
suggesting the urinary metabolic profiles of these groups
of animals were distinct. On a 2-component PCA
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Fig. 1. (A) Baseline hepatic glutathione levels in acetaminophen-na€ıve mice showing reduced glutathione stores in GF mice (P = 0.028,
n = 10 in each group) (B) Hepatic CYP2E1 expression in acetaminophen-na€ıve GF and CH mice as determined by RT-PCR. Graph showing
DCT values calculated by comparison of CYP2E1 expression with geometric mean of three reference genes (B2M, R18s, SDHA) (P = 0.19,
n = 5 in each group) (C) Hepatic CYP2E1 levels in acetaminophen-na€ıve GF and CH mice determined by ELISA.
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Fig. 3. (A) Representative H&E-stained sections from each experimental group showing range of hepatic necrosis from mild/moderate to
severe and haemorrhagic. Magnification (x 40). (B) Hepatic necrosis scores for each experimental group showing no significant differences
between groups.
(A) (B)
(C) (D)
Bi
lir
ub
in
 (µ
m
ol
/l)
G
lu
co
se
 (m
m
ol
/l)
C
re
at
in
in
e 
(µ
m
ol
/l)
AL
T 
(U
/l)
Fig. 2. Biochemistry results 8 h after a toxic acetaminophen dose in experimental groups of germ-free (GF, n = 9), conventionally housed
(CH, n = 20) and LPS-resistant (LPS-r, n = 10) mice. (A) Bilirubin (P = 0.0001) (B) Glucose (P = 0.009) (C) Creatinine P = 0.0001 (D) ALT
P = 0.16
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model, two clusters discriminated along the second PC
were noted (R2X = 0.625, Q2Y = 0.528). A 2-compo-
nent PLS-DA extension gave further discriminatory
accuracy (R2Y = 0.924, 0.844) with a sensitivity and
specificity of 100%. CV-ANOVA statistic was 4 9 108
and from the permutation analysis, the y axis crossing
point was 0, 24 for R2 and -0.31 for Q2. From this valid
model, the following metabolites were determined as
discriminant from the S-loadings plot: creatine and cit-
rate were increased in GF mice and taurine, TMA and
PAG were decreased in GF mice (Fig. 4). These findings
concur with previously published descriptions of the
differences in urinary metabolic profiles between GF
and CH mice (18).
Taurine levels were integrated from the urinary 1H-
NMR spectra of GF and CH mice at T0. GF mice
showed significantly lower baseline urinary taurine than
CH control animals (GF 349.7+/125.8 arbitrary units
CH 664.9 +/165.7 arbitrary units, P = 0.0002) (Fig.
6A).
Acetaminophen metabolism
The metabolic fate of the administered acetaminophen
was compared between the CH and GF groups (Fig. 5).
The urinary acetaminophen-related compounds were
similar between the GF and CH mice at T2, with acet-
aminophen-glucuronide being the dominant metabo-
lite, accounting for 56.6% and 60.3% of the total in GF
and CH mice respectively (Fig. 6B). The S:G ratio,
which had been found to correlate with predose urinary
gut-derived metabolites in humans, was significantly
different between groups at T2 with germ-free mice
showing a relatively greater sulphonation capacity
[0.136 for CH mice and 0.172 for GF mice (P = 0.012)]
(Fig. 6C).
Metabolic response to acetaminophen hepatotoxicity
Comparing the global urinary, NMR response to acet-
aminophen between the time points T0 and T8 in CH
and GF mice at it was clear that the GF mice underwent
a more heterogeneous metabolic response. At T8, unsu-
pervised PCA showed distinct clustering in a 2-compo-
nent model across PC 1 with R2X of 0.77 and Q2 of
0.70. GF status was clearly the discriminating phenotype
with GF animals showing a more divergent response
from this principal component. The PLS-DA extension
had similar robust variance explanation and validation
(R2Y = 0.93, Q2 = 0.89, CV-ANOVA P = 108, permuta-
tion intercepts R2 = 0.20, Q2 = 0.21, sensitivity,
100% specificity 100% between GF status). The PCA
scores plot from a model using all four time points
shows this divergence (Fig. 7A). Cross-validated plots of
all four time points from an OPLS-DA model
(R2Y = 0.888, Q2Y = 0.786) further demonstrate this
(Fig. 7B).
Discussion
Interindividual susceptibility to acetaminophen-induced
hepatotoxicity has long been recognised by clinicians
treating patients who overdose on this medication. One
potential source for this variability is the difference in
patient’s intestinal microbiota, a factor which has been
demonstrated to effect drug metabolism and toxicity in
experimental studies. We hypothesised that the absence
of intestinal microbiota would attenuate the develop-
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Fig. 4. PCA Scores plot of Germ-Free (GF) vs. Control (C) mice. Two-component model R2(Y) = 0.643, Q2(Y) = 0.479
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ment and severity of acute acetaminophen-induced hep-
atotoxicity and that this effect would be partly modu-
lated through reduced LPS–TLR4 signalling. Overall
results have shown that in a murine model of acute,
severe acetaminophen toxicity, the absence of intestinal
microbiota is not associated with a lesser degree of
hepatic injury as shown by hepatic necrosis or ALT lev-
els. However, a milder clinical phenotype with less renal
impairment, lower bilirubin levels and a trend towards
higher plasma glucose was seen in the GF animals.
C & A
S
G
M
C
S S C
C
G G
AM M
ppmppm
ppm
7.5 7.4 7.3 7.2 7.1 7.0 6.9 2.18 2.16 2.14
7.5 7.0 6.58.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Fig. 5. Representative T2 post-dose NMR spectrum demonstrating dominance of acetaminophen metabolites. Expanded views of the aro-
matic and aliphatic regions are given illustrating the peak assignments for A, Acetaminophen; S, Acetaminophen-sulphate; G, Acetamino-
phen-glucuronide; M, Acetaminophen-mercapturate (or N-acetyl-L-cysteinyl); C, L-cysteinyl Acetaminophen.
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Fig. 6. Integrated H1-NMR spectra (A) Baseline (T0) urinary taurine levels in GF and CH mice (normalised to total spectral integral)
P = 0.0002. B and C: Quantification of acetaminophen-related metabolites at 2 h post-dosing expressed as a percentage of total urinary-
excreted acetaminophen-related metabolites. (B) Quantification of five major urinary acetaminophen-related metabolites in GF and CH mice
(C) S:G ratio in GF and CH mice P = 0.012.
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Interestingly, the interindividual variability in
response to acetaminophen-induced hepatotoxicity was
as pronounced in the GF group as the CH group, with
similar standard deviations in the mean ALT and hepa-
tic necrosis score. This suggests that differences in intes-
tinal microbiota are unlikely to underlie the frequently
observed variability in murine models of acetamino-
phen toxicity (8).
The slight protective effect of a sterile GI tract was
observed despite a minor but significant baseline differ-
ence in hepatic glutathione that might predispose germ-
free animals to enhanced cellular injury by the reactive
metabolite of acetaminophen, NAPQI, by limiting
detoxification capacity. CYP2E1 mRNA expression and
protein levels did not significantly differ between groups
at baseline. Our observation that the urinary metabolites
of GF and CH mice show no difference in the propor-
tion of drug metabolised via the toxic intermediate sup-
ports that CYP2E1 activity is not affected by the
presence of intestinal bacteria. Urinary taurine levels
have previously been shown to correlate with hepatic
taurine and higher levels are associated with protection
from hepatotoxicity (19). We have demonstrated that
urinary taurine levels are significantly lower in GF mice
than conventional controls, a factor which again might
be expected to predispose GF mice to a more severe
response to acetaminophen. Overall, these findings
imply that the protective effects of GF status impact at a
later stage in the development of hepatotoxicity, after
the initial metabolism of acetaminophen.
Analysis of urinary acetaminophen metabolites dem-
onstrated that drug metabolism is affected by the pres-
ence of intestinal microbiota, with germ-free animals
displaying a lower urinary ratio of glucuronated:sulpho-
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Fig. 7. (A) PCA scores plot showing GF and C mice at baseline (T0) and T8. R2(Y) = 0.669, Q2(Y) = 0.609. (B) Cross-validated scores plot
from OPLS-DA showing GF and C mice at baseline (T0) and T8. R2(Y) = 0.888, Q2(Y) = 0.786 using three components
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nated acetaminophen 2 h after dosing. This shift in
metabolism may be because of competitive inhibition of
hepatic sulphonation capacity by microbial-derived aro-
matic compounds in those animals with bacterially col-
onised intestines. Early work using gradient elution
HPLC to quantify acetaminophen metabolites in the
urine of germ-free mice also described this relationship,
with a significant increase in the percentage excretion of
acetaminophen as a sulphonated conjugate in germ-free
animals (20). This observation is also consistent with
the human study by Clayton et al. which showed a
decrease in the S:G urinary ratio in healthy subjects with
higher predose bacterially derived p-cresol sulphate lev-
els (10). In our study, the total quantity of acetamino-
phen-sulphate and glucuronide in the urine did not
differ between the CH and GF groups, suggesting any
reduced sulphonation capacity in CH mice was at least
partly compensated for by enhanced glucuronation and
thus, subsequent toxicity is unlikely to have been
affected by this alteration.
The main differences in the biochemical markers of
liver impairment between the GF and CH groups were
protective effects on the development of hyperbilirubi-
naemia, renal impairment and hypoglycaemia in GF
mice. Of interest is the observation that the LPS-r group
of mice, with a genetic polymorphism in their TLR4
receptor, have an even greater protection from renal
impairment, hyperbilirubinaemia and hypoglycaemia,
compared to GF mice. There is also a non-significant
trend for lower levels of cytokines associated with TLR4
and inflammasome activation in these mice. Overall,
this suggests that these mice have an additional protec-
tive factor, beyond simply resistance to LPS. A possible
explanation for this observation is that the TLR4 recep-
tor that is mutated in this mouse strain functions not
only as a PAMP (pathogen-associated molecular pat-
tern) receptor, identifying the bacterial product LPS but
also recognises HMGB1 an important DAMP (damage-
associated molecular pattern) in sterile inflammatory
conditions (21). HMGB1 has been shown to have an
important role in acetaminophen-induced ALF, being a
prognostic marker in human subjects and in murine
models (22, 23). Thus the LPS-r mouse, with its global
impairment in TLR4 signalling, that affects the recogni-
tion of HMGB1 and LPS, has a milder response to liver
injury. TLR4 knockout mice have been shown to be rel-
atively protected from acute sterile liver injury and the
development of extra-hepatic organ dysfunction after
liver injury (24–26). Studies have also demonstrated
that TLR4 antagonists may reduce the extent of liver
injury in acetaminophen- and galactosamine-induced
liver failure models (24, 27).
This study has a number of limitations. The use of a
high dose of acetaminophen to model acute, severe
injury necessarily limited the study duration because of
animal welfare considerations. In this respect, we have
only modelled and investigated the earlier phases of
acetaminophen-induced acute liver injury: when toxic-
ity, hepatocellular necrosis and organ failure first
develop. The later stages, seen in human patients who
go on to develop established ALF with secondary
immune dysfunction and multiple-organ failure, were
not represented. Intestinal microbiota may be particu-
larly influential at this later stage as evidenced by the
divergent metabolic responses of the GF and CH groups
and developing organ dysfunction in the CH group. In
our murine model, the route of delivery of acetamino-
phen was IP as it is preferable to oral gavage in terms of
welfare and dosing consistency. However, this differs
from patients in whom acetaminophen overdose is
almost always taken orally. When administered orally,
acetaminophen is rapidly absorbed from the proximal
small intestine with minimal metabolism by the intesti-
nal wall, hence in both IP and oral dosing the majority
of drug is bioavailable to the liver during first pass
metabolism (28, 29). The effects of intestinal microbiota
are likely to be either remote, in the case of LPS stimula-
tion or during the entero-hepatic circulation of acetami-
nophen metabolites and therefore will not be affected by
the initial drug delivery method.
In conclusion, we have demonstrated that in an acute
toxicity model, the presence of intestinal microbiota
influences the metabolism of acetaminophen by reduc-
ing hepatic sulphonation capacity. Germ-free mice
experience a milder hepatotoxicity phenotype with
lower plasma bilirubin, lower creatinine levels and a
trend towards higher glucose compared to convention-
ally housed animals, despite no significant differences in
the extent of their liver lesion as defined by histology
and plasma ALT. Impairments in TLR4 signalling were
associated with an even greater protection than GF sta-
tus alone, suggesting DAMP signalling through TLR4
plays a significant role in the pathogenesis of acetamino-
phen toxicity. Overall, this study suggests that the pro-
tective effects of a sterile intestine impacts late in the
evolution of acute liver failure, on the metabolic
response to initial injury and the development of extra-
hepatic dysfunction such as renal impairment. In this
respect, the study findings are of particular clinical rele-
vance as delayed patient presentation means the oppor-
tunity for intervention in acetaminophen-induced acute
liver failure is often after the initial liver injury is estab-
lished. This study therefore raises the possibility of ther-
apeutic intervention to modify intestinal microbiota
through gut cleansing antibiotics or pharmacological
inhibition of TLR4 signalling in the treatment of
patients with acute liver failure.
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